# Fortrea Holdings Inc.: overview

FTRE · Nasdaq · CIK 1965040 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ftre.md) · [Financials](/companies/ftre/financials.md) · [Filings](/companies/ftre/filings.md) · [Insiders](/companies/ftre/insiders.md)

Latest reported revenue: [$691.5m](/filings/0001628280-26-068248.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 29, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-068248).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [697 d](/filings/0001628280-26-012244.md) | [651](/filings/0001628280-26-030496.md) | [710](/filings/0001628280-26-050597.md) | [701](/filings/0001628280-26-068248.md) | [661 d](/filings/0001628280-26-012244.md) | [637](/filings/0001628280-26-030496.md) | [678](/filings/0001628280-26-050597.md) | [692](/filings/0001628280-26-068248.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(8.0%) d](/filings/0001628280-26-012244.md) | [(79.9%)](/filings/0001628280-26-030496.md) | [(46.5%)](/filings/0001628280-26-050597.md) | [(1.2%)](/filings/0001628280-26-068248.md) | [(2.1%) d](/filings/0001628280-26-012244.md) | [(0.5%)](/filings/0001628280-26-030496.md) | [2.2%](/filings/0001628280-26-050597.md) | [2.2%](/filings/0001628280-26-068248.md) |
| Net margin | % | [(8.8%) d](/filings/0001628280-26-012244.md) | [(86.4%)](/filings/0001628280-26-068248.md) | [(52.8%)](/filings/0001628280-26-068248.md) | [(2.3%)](/filings/0001628280-26-068248.md) | [(4.9%) d](/filings/0001628280-26-012244.md) | [(3.7%)](/filings/0001628280-26-068248.md) | [(1.9%)](/filings/0001628280-26-068248.md) | [0.1%](/filings/0001628280-26-068248.md) |
| Diluted EPS | $ per share | not reported | [(6.25)](/filings/0001628280-26-030496.md) | [(4.14)](/filings/0001628280-26-050597.md) | [(0.17)](/filings/0001628280-26-068248.md) | not reported | [(0.25)](/filings/0001628280-26-030496.md) | [(0.14)](/filings/0001628280-26-050597.md) | [0.01](/filings/0001628280-26-068248.md) |
| Free cash flow | $m | [13.9 d](/filings/0001628280-26-012244.md) | [(127)](/filings/0001628280-26-030496.md) | [14.3 d](/filings/0001628280-26-050597.md) | [79.5 d](/filings/0001628280-26-068248.md) | [122 d](/filings/0001628280-26-012244.md) | [(25.0)](/filings/0001628280-26-030496.md) | [19.9 d](/filings/0001628280-26-050597.md) | [52.5 d](/filings/0001628280-26-068248.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY (2021-12-31) | FY (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3,058](/filings/0001965040-24-000010.md) | [2,837](/filings/0001965040-25-000015.md) | [2,843](/filings/0001628280-26-012244.md) | [2,696](/filings/0001628280-26-012244.md) | [2,723](/filings/0001628280-26-012244.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [3.7%](/filings/0001965040-24-000010.md) | [6.6%](/filings/0001965040-25-000015.md) | [1.1%](/filings/0001628280-26-012244.md) | [(6.0%)](/filings/0001628280-26-012244.md) | [(32.0%)](/filings/0001628280-26-012244.md) |
| Net margin | % | [3.2%](/filings/0001965040-24-000010.md) | [6.6%](/filings/0001965040-25-000015.md) | [(0.9%)](/filings/0001628280-26-012244.md) | [(12.2%)](/filings/0001628280-26-012244.md) | [(36.2%)](/filings/0001628280-26-012244.md) |
| Diluted EPS | $ per share | [1.10](/filings/0001965040-24-000010.md) | [2.09](/filings/0001965040-25-000015.md) | [(0.29)](/filings/0001628280-26-012244.md) | [(3.67)](/filings/0001628280-26-012244.md) | [(10.81)](/filings/0001628280-26-012244.md) |
| Free cash flow | $m | [143](/filings/0001965040-24-000010.md) | [28.3](/filings/0001965040-25-000015.md) | [128](/filings/0001628280-26-012244.md) | [237](/filings/0001628280-26-012244.md) | [88.3](/filings/0001628280-26-012244.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ftre/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $274.9m | 15,799,104 |  | Added +646,709 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $146.4m | 8,414,011 |  | Added +315,494 |
| [Sessa Capital IM, L.P.](/funds/1595849.md) | 2026-06-30 | $79.9m | 4,593,550 |  | Unchanged |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $72.8m | 4,181,552 |  | Added +142,990 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $66.4m | 3,816,627 |  | Added +119,878 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $65.8m | 3,784,173 |  | Reduced −325,227 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $63.5m | 3,646,931 |  | Added +2,402,794 |
| [Corvex Management LP](/funds/1535472.md) | 2026-06-30 | $52.0m | 2,988,551 |  | Reduced −1,655,642 |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $51.9m | 2,980,474 |  | Reduced −317,947 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $44.3m | 2,546,771 |  | Added +180,294 |

## Recent filings

[All 331 filings](/companies/ftre/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 16:15 ET | [10-Q](/filings/0001628280-26-068248.md) | Quarterly report, period 2026-09-30 | 0001628280-26-068248 |
| 2026-10-29 | 06:38 ET | [8-K](/filings/0001965040-26-000146.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001965040-26-000146 |
| 2026-09-30 | 16:06 ET | [8-K](/filings/0001628280-26-063970.md) | 5.02 Departure or appointment of officers or directors | 0001628280-26-063970 |
| 2026-09-10 | 07:00 ET | [8-K](/filings/0001628280-26-061218.md) | 5.02 Departure or appointment of officers or directors | 0001628280-26-061218 |
| 2026-07-29 | 16:03 ET | [10-Q](/filings/0001628280-26-050597.md) | Quarterly report, period 2026-06-30 | 0001628280-26-050597 |
| 2026-07-29 | 06:36 ET | [8-K](/filings/0001628280-26-050368.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001628280-26-050368 |
| 2026-07-14 | 16:05 ET | [8-K](/filings/0001628280-26-048152.md) | 5.02 Departure or appointment of officers or directors | 0001628280-26-048152 |
| 2026-06-26 | 16:42 ET | [8-K](/filings/0001628280-26-045801.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-045801 |
| 2026-06-12 | 16:04 ET | [8-K](/filings/0001628280-26-042827.md) | 5.07 Shareholder vote results | 0001628280-26-042827 |
| 2026-05-05 | 16:06 ET | [10-Q](/filings/0001628280-26-030496.md) | Quarterly report, period 2026-03-31 | 0001628280-26-030496 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-012244.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, has been scored from the reported figures. [See the target](/leagues/2026q3/targets/f911df70-6a3e-49e7-bd86-867c9f4d2c6a)

## About the filer

- CIK: 1965040
- Tickers: FTRE
- Exchange: Nasdaq
- SIC code: 8071 Services-Medical Laboratories
- State of incorporation: not reported
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 17:51 ET. No prices; not investment advice.